Two Sigma Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$86.8M Sell
266,100
-9,700
-4% -$3.16M 0.18% 125
2025
Q1
$74.5M Buy
275,800
+197,000
+250% +$53.2M 0.17% 126
2024
Q4
$18.5M Sell
78,800
-24,300
-24% -$5.72M 0.04% 337
2024
Q3
$28.4M Sell
103,100
-155,600
-60% -$42.8M 0.07% 252
2024
Q2
$62.9M Buy
258,700
+69,100
+36% +$16.8M 0.14% 140
2024
Q1
$28.3M Buy
+189,600
New +$28.3M 0.07% 271
2023
Q4
Sell
-35,900
Closed -$6.36M 2486
2023
Q3
$6.36M Sell
35,900
-157,700
-81% -$27.9M 0.02% 631
2023
Q2
$36.8M Buy
193,600
+38,500
+25% +$7.31M 0.09% 214
2023
Q1
$31.1M Buy
155,100
+35,100
+29% +$7.03M 0.08% 235
2022
Q4
$28.5M Buy
120,000
+56,200
+88% +$13.4M 0.08% 247
2022
Q3
$12.8M Buy
63,800
+51,400
+415% +$10.3M 0.04% 436
2022
Q2
$1.81M Sell
12,400
-34,300
-73% -$5M 0.01% 1269
2022
Q1
$7.63M Buy
46,700
+42,900
+1,129% +$7.01M 0.02% 624
2021
Q4
$644K Buy
+3,800
New +$644K ﹤0.01% 1781
2021
Q2
Sell
-31,900
Closed -$4.5M 2434
2021
Q1
$4.5M Buy
31,900
+28,200
+762% +$3.98M 0.01% 891
2020
Q4
$481K Buy
+3,700
New +$481K ﹤0.01% 1878
2020
Q3
Sell
-8,300
Closed -$1.23M 2384
2020
Q2
$1.23M Buy
+8,300
New +$1.23M ﹤0.01% 1474
2019
Q2
Sell
-70,800
Closed -$6.62M 2298
2019
Q1
$6.62M Sell
70,800
-46,300
-40% -$4.33M 0.02% 748
2018
Q4
$8.54M Sell
117,100
-72,400
-38% -$5.28M 0.02% 613
2018
Q3
$16.6M Sell
189,500
-44,322
-19% -$3.88M 0.04% 442
2018
Q2
$23M Sell
233,822
-123,400
-35% -$12.2M 0.06% 360
2018
Q1
$42.5M Buy
357,222
+248,200
+228% +$29.6M 0.12% 228
2017
Q4
$13.9M Buy
+109,022
New +$13.9M 0.04% 498
2016
Q2
Sell
-101,622
Closed -$6.38M 2039
2016
Q1
$6.38M Buy
101,622
+97,300
+2,251% +$6.11M 0.04% 447
2015
Q4
$407K Buy
+4,322
New +$407K ﹤0.01% 1404
2015
Q3
Sell
-5,022
Closed -$602K 1794
2015
Q2
$602K Sell
5,022
-1,500
-23% -$180K ﹤0.01% 1354
2015
Q1
$681K Sell
6,522
-900
-12% -$94K 0.01% 1220
2014
Q4
$720K Buy
+7,422
New +$720K 0.01% 1220